Iridex Corporation announced preliminary unaudited operational and financial results for the fourth quarter and full year 2025, showcasing continued growth and operational efficiencies.
The company demonstrated revenue growth, operational efficiencies, and positive cash flow.
Total revenue for the fourth quarter is expected to be between $14.6 million and $14.8 million, reflecting a robust year-over-year growth of 15% to 17%.
Revenue Growth
Iridex expects total revenue for full year 2025 to range between $52.5 million and $52.7 million, marking an 8% increase from 2024.
Positive Cash Flow
The company achieved positive cash flow in the fourth quarter of 2025.
Sales Performance
In Q4 2025, Iridex sold 15,800 Cyclo G6® probes and 44 Cyclo G6 Glaucoma Laser Systems.
- Throughout 2025, Iridex enhanced its financial position by implementing targeted cost reductions and expanding gross margins.
- The company boosted probe sales and attained positive adjusted EBITDA for the year, underpinning its financial health.
- Iridex's strategic initiatives drove a fifth consecutive quarter of year-over-year revenue growth and lowered operating expenses.
Iridex's 2025 strategies and actions led to positive financial outcomes and bolstered performance metrics.